Patents by Inventor Catherine Ghezzi

Catherine Ghezzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-MESOTHELIN RADIOLABELLED SINGLE DOMAIN ANTIBODIES SUITABLE FOR THE IMAGING AND TREATMENT OF CANCERS
    Publication number: 20200197547
    Abstract: Mesothelin (MSLN) has been found to be overexpressed in several human malignancies: 100% of epithelial mesotheliomas, the majority of pancreatic and ovarian adenocarcinomas, more than 50% of lung adenocarcinomas and 34 to 67% of triple negative breast cancer (TNBC). The limited expression of mesothelin in normal human tissues and its overexpression in several aggressive human cancers make MSLN an attractive candidate for therapy. The objective of the inventors was to perform the nuclear imaging of TNBC xenografts with anti-MSLN single domain antibodies radiolabeled with 99mTc (99mTc-A1 and 99mTc-C6). They showed that 99mTc-A1 represent a good candidate for targeting mesothelin positive tumors. Accordingly, the present invention to an anti-mesothelin single domain antibody which is labelled with a radionuclide and its uses for imaging and/or treating cancer.
    Type: Application
    Filed: August 29, 2018
    Publication date: June 25, 2020
    Inventors: Alexis BROISAT, Catherine GHEZZI, Christopher MONTEMAGNO, Daniel FAGRET
  • Anti-tau nanobodies
    Patent number: 10590191
    Abstract: The invention relates to anti-Tau nanobodies.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 17, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Daniel Fagret, Marcelle Moulin, Catherine Ghezzi, Pascale Perret, Sabine Chierici
  • ANTI-TAU NANOBODIES
    Publication number: 20190263898
    Abstract: The invention relates to anti-Tau nanobodies.
    Type: Application
    Filed: October 27, 2017
    Publication date: August 29, 2019
    Inventors: Daniel FAGRET, Marcelle MOULIN, Catherine GHEZZI, Pascale PERRET, Sabine CHIERICI
  • Anti-VCAM-1 nanobodies
    Patent number: 9771423
    Abstract: The present invention relates to nanobodies specifically directed against VCAM-1 and to their use in medical imaging and in diagnostic, prognostic and treatment methods.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: September 26, 2017
    Assignees: VIRJE UNIVERSITEIT BRUSSEL, CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, UNIVERSITE GRENOBLE ALPES
    Inventors: Catherine Ghezzi, Daniel Fagret, Alexis Broisat, Nick Devoogdt, Tony Lahoutte, Serge Muydermans
  • ANTI-VCAM-1 NANOBODIES
    Publication number: 20140255303
    Abstract: The present invention relates to nanobodies specifically directed against VCAM-1 and to their use in medical imaging and in diagnostic, prognostic and treatment methods.
    Type: Application
    Filed: August 22, 2012
    Publication date: September 11, 2014
    Applicant: UNIVERSITE JOSEPH FOURIER- GRENOBLE 1
    Inventors: Catherine Ghezzi, Daniel Fagret, Alexis Broisat, Nick Devoogdt, Tony Lahoutte, Serge Muydermans
  • NON-INVASIVE TOOLS FOR DETECTING VULNERABLE ATHEROSCLEROTIC PLAQUES
    Publication number: 20120034163
    Abstract: The present invention relates to a polypeptide comprising the sequence RILAR (SEQ ID NO: 3), the use thereof in imaging methods, in diagnostic or prognostic methods and for use as a medicament.
    Type: Application
    Filed: January 5, 2010
    Publication date: February 9, 2012
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Daniel Fagret, Catherine Ghezzi, Pascal Dumy, Laurent Riou, Didier Boturyn
  • NOVEL METHOD FOR MEASURING INSULIN RESISTANCE
    Publication number: 20110166428
    Abstract: Method of using at least one glucose derivative, halogenated in the 6 position, for the implementation of a process for the determination of insulin resistance in a mammal, in particular man, by measuring the variation in the quantity (as a function of time) of the derivative in muscle cells during a given period t, after administration of the derivative, and the variation in quantity (as a function of time) of the derivative in the muscle cells during a period essentially equal to the period t, after administration of the derivative, preceded by an administration of insulin.
    Type: Application
    Filed: July 17, 2009
    Publication date: July 7, 2011
    Applicants: UNIVERSITE JOSEPH FOURIER, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Catherine Ghezzi, Daniel Fagret, Jacques Demongeot, Pascale Perret
  • USE OF VCAM-1 LIGANDS FOR DETECTING AND/OR TREATING CARDIOVASCULAR DISEASES
    Publication number: 20090208408
    Abstract: The invention concerns the use of VCAM-1 ligands in medical imagery, in particular for characterizing and/or therapeutic monitoring of cardiovascular diseases and more particularly for detecting vulnerable coronary atheroma. The invention also concerns the use of VCAM-1 ligands for making a medicine for treating a cardiovascular disease.
    Type: Application
    Filed: September 30, 2005
    Publication date: August 20, 2009
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Didier Boturyn, Laurent Riou, Catherine Ghezzi, Daniel Fagret, Pascal Dumy